Quick Answer
ABEONA THERAPEUTICS INC. reported R&D Expense of $26.81 million for fiscal year 2025.
ABEONA THERAPEUTICS INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $26.81M | -22.0% |
| 2024 | $34.36M | +10.5% |
| 2023 | $31.09M | +7.3% |
| 2022 | $28.96M | -25.2% |
| 2021 | $38.73M | +28.5% |
| 2020 | $30.14M | -37.9% |
| 2019 | $48.57M | +25.5% |
| 2018 | $38.70M | +127.8% |
| 2017 | $16.99M | +59.4% |
| 2016 | $10.65M | +126.0% |
| 2015 | $4.71M | +1315.9% |
| 2014 | $333.0K | -62.3% |
| 2013 | $884.0K | -56.0% |
| 2012 | $2.01M | -43.8% |
| 2011 | $3.58M | +6.9% |
| 2010 | $3.35M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.22M | -52.8% | -29.1% |
| June 30, 2025 | $5.94M | -35.5% | -40.2% |
| March 31, 2025 | $9.94M | +37.9% | +11.2% |
| September 30, 2024 | $8.94M | +25.1% | -3.0% |
| June 30, 2024 | $9.22M | +8.2% | +27.9% |
| March 31, 2024 | $7.21M | -10.4% | +0.8% |
| September 30, 2023 | $7.15M | +30.2% | -16.1% |
| June 30, 2023 | $8.52M | +28.0% | +6.0% |
- ABEONA THERAPEUTICS INC. showed a decrease of -22.0% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, ABEONA THERAPEUTICS INC.’s r&d expense has grown by 700.6% (from $3.35 million to $26.81 million).
- The most recent figure is from ABEONA THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: